<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:RENB="http://renovarobio.com/20240930"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="renb-20240930.xsd" xlink:type="simple"/>
    <context id="From2024-07-01to2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_SeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RENB:SeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_SeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RENB:SeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RENB:SeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_SeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RENB:SeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_SeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RENB:SeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RENB:SeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_srt_RestatementAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_AsRestatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">RENB:AsRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-02-122024-02-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_January2024NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:January2024NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_January2024NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:January2024NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-20_custom_January2024NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:January2024NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="From2023-12-012023-12-20_custom_January2024NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:January2024NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-16_custom_September2024NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:September2024NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-16</instant>
        </period>
    </context>
    <context id="From2024-09-012024-09-16_custom_September2024NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:September2024NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-06_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-06</instant>
        </period>
    </context>
    <context id="From2024-09-012024-09-06_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-05_custom_February2024NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:February2024NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="From2024-02-012024-02-05_custom_February2024NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:February2024NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-05_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="AsOf2023-11-03_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="From2024-11-012024-11-03_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-03</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="From2020-03-012020-03-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-20_custom_PurchaseAgreement2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:PurchaseAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="AsOf2023-06-20_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-14_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="From2024-07-032024-09-16_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-03</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-16_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-16</instant>
        </period>
    </context>
    <context id="From2024-07-302024-08-02_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-08-23_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-23</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-11_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-23_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-05</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="From2019-11-142019-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2019-11-14</startDate>
            <endDate>2019-11-15</endDate>
        </period>
    </context>
    <context id="From2021-08-242021-08-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2021-08-24</startDate>
            <endDate>2021-08-25</endDate>
        </period>
    </context>
    <context id="From2021-09-092021-09-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2021-09-09</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_MarkDybulMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:MarkDybulMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_RENBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_RENCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-13_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-11-06</instant>
        </period>
    </context>
    <context id="From2024-10-212024-11-06_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-21</startDate>
            <endDate>2024-11-06</endDate>
        </period>
    </context>
    <context id="From2024-10-212024-11-06_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-21</startDate>
            <endDate>2024-11-06</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-10-17_custom_MZHCILLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">RENB:MZHCILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-17</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-10-14_custom_DavidWeinsteinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">RENB:DavidWeinsteinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-10-14_custom_ConsultingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">RENB:ConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Euro">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-07-01to2024-09-30" id="Fact000003">true</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2024-07-01to2024-09-30" id="Fact000004">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-07-01to2024-09-30" id="Fact000005">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-07-01to2024-09-30" id="Fact000006">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2024-07-01to2024-09-30" id="Fact000007">0001527728</dei:EntityCentralIndexKey>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-07-01to2024-09-30"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0262"
      unitRef="Shares"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0332"
      unitRef="Shares"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-07-012024-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2024-07-012024-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-01to2024-09-30"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_custom_SeriesAPreferredStocksMember"
      id="xdx2ixbrl0391"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-07-01to2024-09-30"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2024-07-01to2024-09-30"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:CancellationOfRestrictedStockAwards
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-012024-09-30_us-gaap_PatentsMember"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2024-07-012024-09-30_us-gaap_PatentsMember"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-07-012024-09-30_us-gaap_PatentsMember"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-012024-09-30_custom_LessAccumulatedAmortizationMember"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-07-012024-09-30_custom_LessAccumulatedAmortizationMember"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-01to2024-09-30"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-07-01to2024-09-30"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-012024-09-30_us-gaap_GoodwillMember"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2024-07-012024-09-30_us-gaap_GoodwillMember"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-01to2024-09-30"
      id="xdx2ixbrl0666"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2024-07-01to2024-09-30"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:BusinessAcquisitionsRevenue
      contextRef="From2024-07-012024-09-30_custom_GEDiCubeMember"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="From2023-07-012023-09-30_custom_GEDiCubeMember"
      id="xdx2ixbrl0949"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-07-01to2024-09-30" id="Fact000014">10-Q/A</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-07-01to2024-09-30" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-07-01to2024-09-30" id="Fact000016">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-07-01to2024-09-30" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-07-01to2024-09-30" id="Fact000018">001-38758</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-07-01to2024-09-30" id="Fact000019">Renovaro Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-07-01to2024-09-30" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-07-01to2024-09-30" id="Fact000021">45-2559340</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-07-01to2024-09-30" id="Fact000022">2080 Century Park East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-07-01to2024-09-30" id="Fact000023">Suite 906</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-07-01to2024-09-30" id="Fact000024">&#160;Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-07-01to2024-09-30" id="Fact000025">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-07-01to2024-09-30" id="Fact000026">90067</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-07-01to2024-09-30" id="Fact000027">305</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-07-01to2024-09-30" id="Fact000028">918-1980</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-07-01to2024-09-30" id="Fact000029">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-07-01to2024-09-30" id="Fact000030">RENB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-07-01to2024-09-30" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-07-01to2024-09-30" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-07-01to2024-09-30" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-07-01to2024-09-30" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-07-01to2024-09-30" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-07-01to2024-09-30" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-07-01to2024-09-30" id="Fact000037">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-11-11"
      decimals="INF"
      id="Fact000039"
      unitRef="Shares">158717342</dei:EntityCommonStockSharesOutstanding>
    <dei:AmendmentDescription contextRef="From2024-07-01to2024-09-30" id="Fact000040">&#160;EXPLANATORY NOTE

&#160;

Renovaro Inc. (the &#x201c;Company&#x201d;,
&#x201c;we&#x201d;, &#x201c;our&#x201d;, or &#x201c;us&#x201d;) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q/A (this
&#x201c;Amendment&#x201d;) to amend its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities
and Exchange Commission (the &#x201c;SEC&#x201d;) on November 14, 2024, (the &#x201c;Q1 2025 Form 10-Q&#x201d;) to (i) restate its financial
statements as of and for the periods September 30, 2024, which should no longer be relied on and are being restated herein; and (ii) describe
the restatement and its impact on previously reported amounts.

&#160;

&#160;We are filing this Amendment
to amend and restate the Q1 2025 Form 10-Q with modifications as necessary to reflect these restatements.

&#160;

Background
of Restatement

&#160;

On February 18, 2025, the
Audit Committee (the &#x201c;Audit Committee&#x201d;) of the Board of Directors of the Company, based on the recommendation of the
Company&#x2019;s management, and after consultation with the Company&#x2019;s independent registered public accounting firm, concluded
that the Company&#x2019;s previously issued unaudited interim condensed consolidated financial statements for the quarter ended
September 30, 2024 contained a material misstatement related to the exercising of certain warrants which impacted the change in fair
value of the contingent consideration liability during the year ended June 30, 2024. Accordingly, those financial statements should
no longer be relied upon. Similarly, related reports filed with the Securities Exchange Commission (the &#x201c;SEC&#x201d;), earnings
releases, press releases, shareholder communications, investor presentations or other communications describing relevant portions of
the September 30, 2024, financial statements should no longer be relied upon. The Company is restating the September 30, 2024,
financial statements within this Amendment.

&#160;

During the preparation of the Company&#x2019;s
Form 10-Q for the period ended December 31, 2024, the Company determined that certain warrants which were exercised during the three months
ended March 31, 2024, had not been appropriately reflected as a component of the change in fair value of the contingent consideration
during the three and nine months ended March 31, 2024. This impacted the September 30, 2024 consolidated balance sheet and September 30,
2024 statement of stockholders&#x2019; equity.

&#160;

Refer to &#x201c;Note 2 -&#160;Restatement
of Previously Issued Financial Statements&#x201d; of &#x201c;Part I - Item 1. Financial Statements&#x201d; (&#x201c;Note 2&#x201d;) for
additional information.

&#160;

Internal
Control Considerations

&#160;

Due to discovery of the error,
the Company&#x2019;s management re-evaluated the effectiveness of the Company&#x2019;s internal control over financial reporting (&#x201c;ICFR&#x201d;)
as of September 30, 2024 and believes the error relates to and is the result of a previously identified and reported material weakness
which has been disclosed in our Form 10-K/A filed on February [], 2025. The material weakness remained in place as of September 30, 2024.
For a discussion of management&#x2019;s consideration of disclosure controls and procedures, internal controls over financial reporting
and the material weaknesses identified, see &#x201c;Part I - Item 4. Controls and Procedures&#x201d; of this Amendment.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">220571</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000049"
      unitRef="USD">220467</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000051"
      unitRef="USD">1242360</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000052"
      unitRef="USD">1108247</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000054"
      unitRef="USD">485228</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000055"
      unitRef="USD">668929</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000057"
      unitRef="USD">1948159</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">1997643</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000060"
      unitRef="USD">452212</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000061"
      unitRef="USD">482121</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000066"
      unitRef="USD">28750</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000067"
      unitRef="USD">30043</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000069"
      unitRef="USD">118171345</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">159330161</us-gaap:Goodwill>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000072"
      unitRef="USD">81697</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">19849</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000075"
      unitRef="USD">1150474</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">1269633</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000078"
      unitRef="USD">119432266</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">160649686</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000081"
      unitRef="USD">121832637</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000082"
      unitRef="USD">163129450</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000090"
      unitRef="USD">11402223</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000091"
      unitRef="USD">9448683</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000093"
      unitRef="USD">5359454</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000094"
      unitRef="USD">5311324</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000096"
      unitRef="USD">102741</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000097"
      unitRef="USD">295361</us-gaap:OtherLiabilitiesCurrent>
    <RENB:ContingentConsiderationLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000099"
      unitRef="USD">3060000</RENB:ContingentConsiderationLiabilityCurrent>
    <RENB:ContingentConsiderationLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000100"
      unitRef="USD">12310000</RENB:ContingentConsiderationLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000102"
      unitRef="USD">245000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000103"
      unitRef="USD">245000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000105"
      unitRef="USD">504254</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000106"
      unitRef="USD">493553</us-gaap:OperatingLeaseLiabilityCurrent>
    <RENB:NotesPayableRelatedPartiesNetCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000108"
      unitRef="USD">2361707</RENB:NotesPayableRelatedPartiesNetCurrent>
    <RENB:NotesPayableRelatedPartiesNetCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000109"
      unitRef="USD">2205996</RENB:NotesPayableRelatedPartiesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000111"
      unitRef="USD">23035379</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000112"
      unitRef="USD">30309917</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000117"
      unitRef="USD">710260</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000118"
      unitRef="USD">842389</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000120"
      unitRef="USD">710260</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000121"
      unitRef="USD">842389</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000123"
      unitRef="USD">23745639</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000124"
      unitRef="USD">31152306</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000135"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000137"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000132"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000133"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000154"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000156"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">161042767</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">161042767</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">158452644</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">158452644</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000151"
      unitRef="USD">16106</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000152"
      unitRef="USD">15847</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">468440794</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000171"
      unitRef="USD">464587224</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000173"
      unitRef="USD">-376667117</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-332455081</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000176"
      unitRef="USD">6297215</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">-170846</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">98086998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">131977144</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000182"
      unitRef="USD">121832637</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">163129450</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000188"
      unitRef="USD">5301251</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">8290210</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000191"
      unitRef="USD">390189</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000192"
      unitRef="USD">566644</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">47614729</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000197"
      unitRef="USD">32385</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000198"
      unitRef="USD">27260</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">53338554</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">8884114</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000203"
      unitRef="USD">-53338554</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-8884114</us-gaap:OperatingIncomeLoss>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000209"
      unitRef="USD">9250000</RENB:ChangeInFairValueOfContingentConsideration>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000213"
      unitRef="USD">-120018</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000215"
      unitRef="USD">250080</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">179271</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000218"
      unitRef="USD">126598</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">8375</us-gaap:InterestAndOtherIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000221"
      unitRef="USD">9126518</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">-290914</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-9175028</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="Fact000227"
      unitRef="USDPShares">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="Fact000229"
      unitRef="USDPShares">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000231"
      unitRef="USDPShares">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000233"
      unitRef="USDPShares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="Fact000235"
      unitRef="Shares">1</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="Fact000237"
      unitRef="Shares">1</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000239"
      unitRef="Shares">64480753</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000241"
      unitRef="Shares">64480753</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000243"
      unitRef="USD">-44212036</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000244"
      unitRef="USD">-9175028</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-6468061</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000250"
      unitRef="USD">34601</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000252"
      unitRef="USD">-37743975</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000253"
      unitRef="USD">-9209629</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">63698144</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">6371</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">290554875</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-244029253</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-29882</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000260"
      unitRef="USD">46502111</us-gaap:StockholdersEquity>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares
      contextRef="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">280505</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">28</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">1999972</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000271"
      unitRef="USD">2000000</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionShares
      contextRef="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember"
      decimals="INF"
      id="Fact000282"
      unitRef="Shares">280505</RENB:IssuanceOfPreferredStockAndWarrantsForConversionShares>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue
      contextRef="From2023-07-012023-09-30_custom_SeriesAPreferredStocksMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">28</RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">1999973</RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000280"
      unitRef="USD">2000001</RENB:IssuanceOfPreferredStockAndWarrantsForConversionValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedShares
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">2000000</RENB:RestrictedSharesIssuedForServicesRenderedShares>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">200</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">4469800</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000289"
      unitRef="USD">4470000</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">983829</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000298"
      unitRef="USD">983829</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">-9175028</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000305"
      unitRef="USD">-9175028</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000311"
      unitRef="USD">-34601</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000312"
      unitRef="USD">-34601</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_custom_SeriesAPreferredStocksMember"
      decimals="INF"
      id="Fact000321"
      unitRef="Shares">561010</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_SeriesAPreferredStocksMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">56</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000323"
      unitRef="Shares">65598144</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">6571</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">300008449</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">-253204281</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">-64483</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact000319"
      unitRef="USD">46746312</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000334"
      unitRef="Shares">158452644</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">15847</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">464587224</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">-332455081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-170846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000330"
      unitRef="USD">131977144</us-gaap:StockholdersEquity>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingShares
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000343"
      unitRef="Shares">1423456</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingShares>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000337"
      unitRef="USD">142</RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">2096039</RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000341"
      unitRef="USD">2096181</RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering>
    <RENB:RestrictedSharesIssuedForServicesRenderedShares
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000352"
      unitRef="Shares">2000000</RENB:RestrictedSharesIssuedForServicesRenderedShares>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">200</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">1399800</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000350"
      unitRef="USD">1400000</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000361"
      unitRef="Shares">-833333</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">-83</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">83</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">357648</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000368"
      unitRef="USD">357648</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000381"
      unitRef="USD">6468061</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000382"
      unitRef="USD">6468061</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">161042767</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">16106</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">468440794</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">-376667117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000388"
      unitRef="USD">6297215</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000389"
      unitRef="USD">98086998</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000398"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000399"
      unitRef="USD">-9175028</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000404"
      unitRef="USD">32385</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000405"
      unitRef="USD">27260</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000408"
      unitRef="USD">-120018</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000410"
      unitRef="USD">9250000</RENB:ChangeInFairValueOfContingentConsideration>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000413"
      unitRef="USD">357648</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000414"
      unitRef="USD">983829</us-gaap:ShareBasedCompensation>
    <RENB:RestrictedSharesForServicesRendered
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000416"
      unitRef="USD">1400000</RENB:RestrictedSharesForServicesRendered>
    <RENB:RestrictedSharesForServicesRendered
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000417"
      unitRef="USD">4470000</RENB:RestrictedSharesForServicesRendered>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000419"
      unitRef="USD">47614729</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000420"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <RENB:AmortizationOfDiscountOnNotePayable
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000422"
      unitRef="USD">23718</RENB:AmortizationOfDiscountOnNotePayable>
    <RENB:AmortizationOfDiscountOnNotePayable
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000423"
      unitRef="USD">167765</RENB:AmortizationOfDiscountOnNotePayable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000428"
      unitRef="USD">195961</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000429"
      unitRef="USD">-0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-183701</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000432"
      unitRef="USD">-411352</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000434"
      unitRef="USD">1953539</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000435"
      unitRef="USD">124303</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000437"
      unitRef="USD">46891</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000438"
      unitRef="USD">77055</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000440"
      unitRef="USD">31325</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000441"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000443"
      unitRef="USD">-2269</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000444"
      unitRef="USD">-16239</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000446"
      unitRef="USD">-2016328</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-2777207</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000453"
      unitRef="USD">1057875</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000455"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000456"
      unitRef="USD">-1057875</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000461"
      unitRef="USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000462"
      unitRef="USD">750000</us-gaap:ProceedsFromConvertibleDebt>
    <RENB:RepaymentOfFinanceAgreement
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000464"
      unitRef="USD">223945</RENB:RepaymentOfFinanceAgreement>
    <RENB:RepaymentOfFinanceAgreement
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000465"
      unitRef="USD">187183</RENB:RepaymentOfFinanceAgreement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000467"
      unitRef="USD">2096181</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000468"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000470"
      unitRef="USD">156947</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000471"
      unitRef="USD">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000473"
      unitRef="USD">2029183</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000474"
      unitRef="USD">2562817</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-12751</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000477"
      unitRef="USD">-78741</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000479"
      unitRef="USD">104</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000480"
      unitRef="USD">-1351006</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000482"
      unitRef="USD">220467</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000483"
      unitRef="USD">1874480</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000485"
      unitRef="USD">220571</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact000486"
      unitRef="USD">523474</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000494"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000495"
      unitRef="USD">5256</us-gaap:InterestPaidNet>
    <RENB:ConversionOfNotePayableForIssuanceOfPreferredStock
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000500"
      unitRef="USD">0</RENB:ConversionOfNotePayableForIssuanceOfPreferredStock>
    <RENB:ConversionOfNotePayableForIssuanceOfPreferredStock
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000501"
      unitRef="USD">2000001</RENB:ConversionOfNotePayableForIssuanceOfPreferredStock>
    <RENB:DebtDiscountRelatedToConvertiblePromissoryNotes
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000503"
      unitRef="USD">24954</RENB:DebtDiscountRelatedToConvertiblePromissoryNotes>
    <RENB:DebtDiscountRelatedToConvertiblePromissoryNotes
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000504"
      unitRef="USD">39474</RENB:DebtDiscountRelatedToConvertiblePromissoryNotes>
    <RENB:CancellationOfRestrictedStockAwards
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000506"
      unitRef="USD">83</RENB:CancellationOfRestrictedStockAwards>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000509">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zV96sWcUue9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_823_zbXiMWyesCo5"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--BusinessPolicyTextBlock_zqdMVX4vtml2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_866_ztAqjcuzOv28"&gt;Business&lt;/span&gt;
&#x2013;&lt;/b&gt;&#160;On February 13, 2024, the Company changed its corporate name from Renovaro
Biosciences Inc. to Renovaro Inc. (&#x201c;Renovaro&#x201d;, and together with its subsidiaries, the &#x201c;Company&#x201d;, &#x201c;we&#x201d;
or &#x201c;us&#x201d;). Renovaro Inc. operates through two subsidiaries, Renovaro Biosciences and Renovaro Cube. Renovaro Cube refers to
Renovaro Cube Intl Ltd. (formerly known as GediCube Intl. Ltd.) and its wholly owned subsidiaries GediCube, B.V. and Grace Systems B.V.,
which were acquired on February 13, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Renovaro Biosciences is a biotechnology
company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term
or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human
Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible
detection of cancer and its recurrence. Renovaro Cube has developed a proprietary AI platform that analyzes genetics using Explainable
AI to provide earlier and more accurate cancer diagnosis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z14GfB5MQ2W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z82YKSIMb2y"&gt;Basis of Presentation&lt;/span&gt; &#x2013;
&lt;/b&gt;The Company prepares consolidated financial statements in accordance with accounting
principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and follows the rules and regulations of the U.S.
Securities and Exchange Commission (&#x201c;SEC&#x201d;). The accompanying financial statements are unaudited. In the opinion of management,
all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations
and cash flows at September 30, 2024, and 2023 and for the periods then ended have been made. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited
condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in
the Company&#x2019;s June 30, 2024 audited financial statements. The results of operations for the period ended September 30, 2024 are
not necessarily indicative of the operating results for the full year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zsubgg1Ze1Pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zrLjoixosCFk"&gt;Consolidation&lt;/span&gt; &#x2013;&lt;/b&gt; For
the three months ended September 30, 2024, and 2023, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zJF3QH0HmMK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z2slANQ4tcI8"&gt;Accounting Estimates&lt;/span&gt; &#x2013;&lt;/b&gt;
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the
date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ
from those estimated. Significant estimates include the fair value of assets acquired in a business acquisition, contingent consideration,
and equity instruments issued for goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zno6J9Ek9BDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zvRbmAhPXlZj"&gt;Functional Currency &amp;amp; Foreign
Currency Translation&lt;/span&gt; &lt;/b&gt;&#x2013; The functional currency of Renovaro Biosciences Denmark ApS is the Danish Kroner (&#x201c;DKK&#x201d;)
and the functional currency of Renovaro Cube is the Euro (&#x201c;EUR&#x201d;). The Company&#x2019;s reporting currency is the U.S. Dollar
for the purpose of these financial statements. The Company&#x2019;s balance sheet accounts are translated into U.S. dollars at the period-end
exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods
ended September 30, 2024, and 2023. Translation gains and losses are deferred and accumulated as a component of other comprehensive income
in stockholders&#x2019; equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in
a currency other than the functional currency are included in the statement of operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zR5H1pY6bLo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zsjXKMRkZG9k"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt;&lt;/b&gt; &#x2013; In November 2023, the FASB issued ASU 2023-07, &#x201c;&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures&lt;/i&gt;,&#x201d; which requires a public entity to disclose significant segment expenses and other segment items on an
annual and interim basis and to provide in interim periods all disclosures about reportable segment&#x2019;s profit or loss and assets
that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this ASU on July 1, 2024. The
adoption of this ASU had no impact on the Company's condensed consolidated financial statements.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"&gt;In December
2023, the FASB issued ASU 2023-09, &#x201c;&lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;,&#x201d; which enhances
the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation
of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments
to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with
early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently
evaluating the impact this standard will have on its condensed consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"&gt;The Company
currently believes there are no other issued and not yet effective accounting standards that are materially relevant to our condensed
consolidated financial statements.&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <RENB:BusinessPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000511">&lt;p id="xdx_846_ecustom--BusinessPolicyTextBlock_zqdMVX4vtml2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_866_ztAqjcuzOv28"&gt;Business&lt;/span&gt;
&#x2013;&lt;/b&gt;&#160;On February 13, 2024, the Company changed its corporate name from Renovaro
Biosciences Inc. to Renovaro Inc. (&#x201c;Renovaro&#x201d;, and together with its subsidiaries, the &#x201c;Company&#x201d;, &#x201c;we&#x201d;
or &#x201c;us&#x201d;). Renovaro Inc. operates through two subsidiaries, Renovaro Biosciences and Renovaro Cube. Renovaro Cube refers to
Renovaro Cube Intl Ltd. (formerly known as GediCube Intl. Ltd.) and its wholly owned subsidiaries GediCube, B.V. and Grace Systems B.V.,
which were acquired on February 13, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Renovaro Biosciences is a biotechnology
company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term
or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human
Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible
detection of cancer and its recurrence. Renovaro Cube has developed a proprietary AI platform that analyzes genetics using Explainable
AI to provide earlier and more accurate cancer diagnosis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</RENB:BusinessPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000513">&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z14GfB5MQ2W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z82YKSIMb2y"&gt;Basis of Presentation&lt;/span&gt; &#x2013;
&lt;/b&gt;The Company prepares consolidated financial statements in accordance with accounting
principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and follows the rules and regulations of the U.S.
Securities and Exchange Commission (&#x201c;SEC&#x201d;). The accompanying financial statements are unaudited. In the opinion of management,
all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations
and cash flows at September 30, 2024, and 2023 and for the periods then ended have been made. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited
condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in
the Company&#x2019;s June 30, 2024 audited financial statements. The results of operations for the period ended September 30, 2024 are
not necessarily indicative of the operating results for the full year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000515">&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zsubgg1Ze1Pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zrLjoixosCFk"&gt;Consolidation&lt;/span&gt; &#x2013;&lt;/b&gt; For
the three months ended September 30, 2024, and 2023, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-07-01to2024-09-30" id="Fact000517">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zJF3QH0HmMK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z2slANQ4tcI8"&gt;Accounting Estimates&lt;/span&gt; &#x2013;&lt;/b&gt;
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the
date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ
from those estimated. Significant estimates include the fair value of assets acquired in a business acquisition, contingent consideration,
and equity instruments issued for goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000519">&lt;p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zno6J9Ek9BDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zvRbmAhPXlZj"&gt;Functional Currency &amp;amp; Foreign
Currency Translation&lt;/span&gt; &lt;/b&gt;&#x2013; The functional currency of Renovaro Biosciences Denmark ApS is the Danish Kroner (&#x201c;DKK&#x201d;)
and the functional currency of Renovaro Cube is the Euro (&#x201c;EUR&#x201d;). The Company&#x2019;s reporting currency is the U.S. Dollar
for the purpose of these financial statements. The Company&#x2019;s balance sheet accounts are translated into U.S. dollars at the period-end
exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods
ended September 30, 2024, and 2023. Translation gains and losses are deferred and accumulated as a component of other comprehensive income
in stockholders&#x2019; equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in
a currency other than the functional currency are included in the statement of operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000521">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zR5H1pY6bLo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zsjXKMRkZG9k"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt;&lt;/b&gt; &#x2013; In November 2023, the FASB issued ASU 2023-07, &#x201c;&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures&lt;/i&gt;,&#x201d; which requires a public entity to disclose significant segment expenses and other segment items on an
annual and interim basis and to provide in interim periods all disclosures about reportable segment&#x2019;s profit or loss and assets
that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this ASU on July 1, 2024. The
adoption of this ASU had no impact on the Company's condensed consolidated financial statements.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"&gt;In December
2023, the FASB issued ASU 2023-09, &#x201c;&lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;,&#x201d; which enhances
the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation
of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments
to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with
early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently
evaluating the impact this standard will have on its condensed consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"&gt;The Company
currently believes there are no other issued and not yet effective accounting standards that are materially relevant to our condensed
consolidated financial statements.&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <RENB:RestatementPreviouslyIssuedFinancialStatementsTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000526">&lt;p id="xdx_802_ecustom--RestatementPreviouslyIssuedFinancialStatementsTextBlock_zej5bPHemjQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_824_zNxCgVENtP5j"&gt;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the preparation of the
Company&#x2019;s Form 10-Q for the period ended December 31, 2024, the Company determined that certain warrants which were exercised during
the three months ended March 31, 2024, had not been appropriately reflected as a component of the change in fair value of the contingent
consideration for the year ended June 30, 2024. The number of shares underlying these warrants was &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630_z5nESJ2LT70f" title="Underlying these warrants"&gt;3,425,399&lt;/span&gt; which had a fair value of
$&lt;span id="xdx_907_eus-gaap--AssetsFairValueAdjustment_c20240701__20240930_zX4BR3dcp0a" title="Fair value"&gt;7,775,656&lt;/span&gt; on the date of exercise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The impact of the restatement
on these financial statements by line item is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zI8K6v8FoqW7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zWgCIQ4DreBh" style="display: none"&gt;&#160;Schedule of restatement
on these financial statements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20240930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zAHo0hoFrGvh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20240930__srt--RestatementAxis__srt--RestatementAdjustmentMember_zCkU0vtJOiYi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20240930__srt--RestatementAxis__custom--AsRestatedMember_zgxCdRjAIWce" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Change&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CommonStockValue_iI_z0KqjyAcHZy2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;15,763&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;343&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;16,106&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_zIT1a6gGXNLb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;460,665,481&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,775,313&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;468,440,794&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zYwppYKWOJ0h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(368,891,461&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,775,656&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(376,667,117&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

</RENB:RestatementPreviouslyIssuedFinancialStatementsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000528"
      unitRef="Shares">3425399</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000530"
      unitRef="USD">7775656</us-gaap:AssetsFairValueAdjustment>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000532">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zI8K6v8FoqW7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zWgCIQ4DreBh" style="display: none"&gt;&#160;Schedule of restatement
on these financial statements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20240930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zAHo0hoFrGvh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20240930__srt--RestatementAxis__srt--RestatementAdjustmentMember_zCkU0vtJOiYi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20240930__srt--RestatementAxis__custom--AsRestatedMember_zgxCdRjAIWce" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Change&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CommonStockValue_iI_z0KqjyAcHZy2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;15,763&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;343&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;16,106&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_zIT1a6gGXNLb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;460,665,481&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,775,313&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;468,440,794&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zYwppYKWOJ0h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(368,891,461&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,775,656&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(376,667,117&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000534"
      unitRef="USD">15763</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30_srt_RestatementAdjustmentMember"
      decimals="0"
      id="Fact000535"
      unitRef="USD">343</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30_custom_AsRestatedMember"
      decimals="0"
      id="Fact000536"
      unitRef="USD">16106</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000538"
      unitRef="USD">460665481</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-09-30_srt_RestatementAdjustmentMember"
      decimals="0"
      id="Fact000539"
      unitRef="USD">7775313</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-09-30_custom_AsRestatedMember"
      decimals="0"
      id="Fact000540"
      unitRef="USD">468440794</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">-368891461</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30_srt_RestatementAdjustmentMember"
      decimals="0"
      id="Fact000543"
      unitRef="USD">-7775656</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30_custom_AsRestatedMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">-376667117</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000546">&lt;p id="xdx_80B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zOj1DDPscxme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_828_zPdCFkVExNzc"&gt;GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company&#x2019;s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company&#x2019;s continuing operations, and is dependent on additional
financing to fund operations. The Company incurred a net loss of $&lt;span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20240701__20240930_zNlcZMko2ri" title="Net loss"&gt;44,212,036&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20230930_zucR5qinsunf" title="Net loss"&gt;9,175,028&lt;/span&gt; for the quarters ended September 30, 2024
and 2023, respectively. As of September 30, 2024, the Company had cash and cash equivalents of $&lt;span id="xdx_904_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20240930_z7UbtJN3nmg7" title="Cash and cash equivalents"&gt;220,571&lt;/span&gt; and an accumulated deficit of
$&lt;span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20240930_z46GrRI9k9cj" title="Accumulated deficit"&gt;376,667,117&lt;/span&gt; and a working capital deficit of $&lt;span id="xdx_909_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20240930_zD7iDDACywz8" title="Working capital deficit"&gt;21,087,220&lt;/span&gt;. These conditions raise substantial doubt about the Company&#x2019;s ability
to continue as a going concern for one year after the date the financial statements are issued. The consolidated financial statements
do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities
that might be necessary should the Company be unable to continue in existence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Management has reduced overhead and administrative costs by streamlining the organization
to focus around the development and validation of its AI-driven cancer diagnostics platform. The Company has tailored its workforce to
focus on these activities. In addition, the Company intends to secure additional required funding through equity or debt financing. However,
there can be no assurance that the Company will be able to obtain any sources of funding. Such additional funding may not be available
or may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant additional
dilution to our stockholders. If we do not obtain required additional equity or debt funding, our cash resources will be depleted and
we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock
price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained.
If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that
could result in our stockholders losing some or all of their investment in us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;Funding that we may receive during the fiscal year
2025 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support commercialization
of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building working capital
reserves.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000548"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000550"
      unitRef="USD">-9175028</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000552"
      unitRef="USD">220571</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000554"
      unitRef="USD">-376667117</us-gaap:RetainedEarningsAccumulatedDeficit>
    <RENB:WorkingCapitalDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000556"
      unitRef="USD">21087220</RENB:WorkingCapitalDeficit>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000558">&lt;p id="xdx_80A_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zYefiYSJhxh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2014; &lt;span id="xdx_82F_zkFPGQOiAyC4"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company accounts for fair value
measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#x201c;Fair Value Measurements&#x201d;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;There were no Level 1, 2 or 3 assets,
nor any Level 1 or 2 liabilities as of September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Unless otherwise disclosed, the
fair value of the Company&#x2019;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Level 3 liabilities held as of September 30, 2024, consisted of a contingent consideration
liability related to the February 13, 2014 acquisition of &lt;span style="background-color: white"&gt;Renovaro Cube, (the &#x201c;Acquisition&#x201d;).
As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) 70,834,183 shares of Common Stock, (ii) the right
to receive contingent shares pro rata upon the exercise of convertible notes, options, and warrants, which were outstanding at closing
less (iii) an as of yet undefined discount of the number of shares to be issued as a result of any such exercise. The Company and the
stockholders of Renovaro Cube have not determined or agreed on the amount of any such discount which may be applied towards future exercises.
The contingent consideration liability was recorded at fair value of $20,557,500 at the time of the Acquisition and is subsequently remeasured
to fair value at the end of each reporting period. As of September 30, 2024, there were 7,613,301 contingent shares issuable in connection
with the&lt;/span&gt; Acquisition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The fair value of the contingent consideration liability is estimated using
a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs to the model are all contractual or observable
with the exception being volatility, which is computed based on the volatility of the Company&#x2019;s underlying stock. The key inputs
to valuing the contingent consideration liability as of September 30, 2024, were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--FairValueConcentrationOfRiskTextBlock_zPS3WvDv72M2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zHaExX5zaE86" style="display: none"&gt;Schedule of contingent consideration liability&lt;/span&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pip0_c20240930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zummArLsaLnl" title="Stock Price"&gt;0.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z6p0nCN3HZRk" title="Exercise Price"&gt;0.46&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zBkWJGrHM1J5" title="Exercise Price"&gt;8.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zOyAyxkR4zka" title="Volatility"&gt;113&lt;/span&gt;% - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5yNHeBAuerb" title="Volatility"&gt;134&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk Free Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zqWfSoN7uMv9" title="Risk Free Rate"&gt;3.52&lt;/span&gt;% - &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zKaVqiBz5SE2" title="Risk Free Rate"&gt;4.31&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20240930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zqw2TOjfwNIe" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5zZbZlkY419" title="Expected Term (years)"&gt;0.48&lt;/span&gt; &#x2013; &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5JTDhjJIkse" title="Expected Term (years)"&gt;9.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zzyIwlOKJm4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The following table sets forth
the Level 3 liability at September 30, 2024, which is recorded on the consolidated balance sheet at fair value on a recurring basis.
As required, this liability is classified based on the lowest level of input that is significant to the fair value measurement:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3uKEet8ACN6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_z6Bz1xVIwwOe" style="display: none"&gt;Schedule of fair value measurement on recurring basis&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;br/&gt; &lt;br/&gt;
Reporting Date Using&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets for Identical Assets Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other Unobservable Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;The roll forward of the contingent consideration liability is as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt"&gt;Balance June 30, 2024&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zBSS6874mFtb" style="width: 11%; text-align: right" title="Contingent consideration liability, beginning balance"&gt;&#x97;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVoqP2jFSazg" style="width: 11%; text-align: right" title="Contingent consideration liability, beginning balance"&gt;&#x97;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z78uRptqx7Bk" style="width: 11%; text-align: right" title="Contingent consideration liability, beginning balance"&gt;12,310,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Fair value adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LiabilitiesFairValueAdjustment_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;&#x97;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueAdjustment_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;&#x97;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueAdjustment_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;(9,250,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent Consideration Liability at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zz44rxZXbmgb" style="border-bottom: Black 2.5pt double; text-align: right" title="Contingent consideration liability, ending balance"&gt;&#x97;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z2EtKYXlPV02" style="border-bottom: Black 2.5pt double; text-align: right" title="Contingent consideration liability, ending balance"&gt;&#x97;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgipFkSN6UHe" style="border-bottom: Black 2.5pt double; text-align: right" title="Contingent consideration liability, ending balance"&gt;3,060,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8A0_zCjvvKGu4Afc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000562">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--FairValueConcentrationOfRiskTextBlock_zPS3WvDv72M2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zHaExX5zaE86" style="display: none"&gt;Schedule of contingent consideration liability&lt;/span&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pip0_c20240930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zummArLsaLnl" title="Stock Price"&gt;0.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z6p0nCN3HZRk" title="Exercise Price"&gt;0.46&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zBkWJGrHM1J5" title="Exercise Price"&gt;8.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zOyAyxkR4zka" title="Volatility"&gt;113&lt;/span&gt;% - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5yNHeBAuerb" title="Volatility"&gt;134&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk Free Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zqWfSoN7uMv9" title="Risk Free Rate"&gt;3.52&lt;/span&gt;% - &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zKaVqiBz5SE2" title="Risk Free Rate"&gt;4.31&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20240930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zqw2TOjfwNIe" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5zZbZlkY419" title="Expected Term (years)"&gt;0.48&lt;/span&gt; &#x2013; &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5JTDhjJIkse" title="Expected Term (years)"&gt;9.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-09-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000564"
      unitRef="USDPShares">0.48</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000566"
      unitRef="USDPShares">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000568"
      unitRef="USDPShares">8.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012024-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000570"
      unitRef="Pure">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012024-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000572"
      unitRef="Pure">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012024-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000574"
      unitRef="Pure">0.0352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012024-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000576"
      unitRef="Pure">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-07-012024-09-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000578"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-07-012024-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      id="Fact000580">P0Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-07-012024-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      id="Fact000582">P9Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000584">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3uKEet8ACN6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_z6Bz1xVIwwOe" style="display: none"&gt;Schedule of fair value measurement on recurring basis&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;br/&gt; &lt;br/&gt;
Reporting Date Using&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets for Identical Assets Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other Unobservable Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;The roll forward of the contingent consideration liability is as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt"&gt;Balance June 30, 2024&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zBSS6874mFtb" style="width: 11%; text-align: right" title="Contingent consideration liability, beginning balance"&gt;&#x97;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVoqP2jFSazg" style="width: 11%; text-align: right" title="Contingent consideration liability, beginning balance"&gt;&#x97;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z78uRptqx7Bk" style="width: 11%; text-align: right" title="Contingent consideration liability, beginning balance"&gt;12,310,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Fair value adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LiabilitiesFairValueAdjustment_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;&#x97;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueAdjustment_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;&#x97;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueAdjustment_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;(9,250,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent Consideration Liability at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zz44rxZXbmgb" style="border-bottom: Black 2.5pt double; text-align: right" title="Contingent consideration liability, ending balance"&gt;&#x97;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z2EtKYXlPV02" style="border-bottom: Black 2.5pt double; text-align: right" title="Contingent consideration liability, ending balance"&gt;&#x97;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pp0p0_c20240701__20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgipFkSN6UHe" style="border-bottom: Black 2.5pt double; text-align: right" title="Contingent consideration liability, ending balance"&gt;3,060,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000590"
      unitRef="USD">12310000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-07-012024-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000596"
      unitRef="USD">-9250000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000602"
      unitRef="USD">3060000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000606">&lt;p id="xdx_803_eus-gaap--IntangibleAssetsDisclosureTextBlock_zbLkV6cXtBSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_82F_zPKoAYIRqrr3"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Renovaro
Cube, the Company acquired goodwill valued at $&lt;span id="xdx_90B_eus-gaap--GoodwillAcquiredDuringPeriod_c20240212__20240213_zhmxldEfdwpa" title="Goodwill valued"&gt;159,464,039&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;Impairment &#x2013; During the quarter ended September 30, 2024, the results of the assessment indicated
that the carrying value of the RENC reporting unit exceeded its fair value, due to the decline in the estimated fair value of the reporting
unit based on the Company&#x2019;s market capitalization. Management concluded the significant driver for the change in the economic benefits
was due to the Company&#x2019;s continued inability to raise capital for the further development of the technologies within this reporting
unit. Therefore, an impairment adjustment of $&lt;span id="xdx_90F_eus-gaap--GoodwillImpairmentLoss_c20240701__20240930_zf3V7a33xwdl" title="Goodwill impairment adjustment"&gt;47,614,729&lt;/span&gt; was recorded for the period ended September
30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;At September 30, 2024 and June
30, 2024, definite-life and indefinite-life intangible assets consisted of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zX9HuSc029Bi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;span id="xdx_8BB_zEliGgyEuYck" style="display: none"&gt;Schedule of definite-life and indefinite-life intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJLKtksSICy6" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGwZpO5MmZE5" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;284,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0618"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NetDefinitelifeIntangibleAssetsAmortization_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0620"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0622"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;11,644&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1otNi1LCG0i" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending"&gt;296,621&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zi6qMQiBQoY5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(254,934&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(2,501&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(10,436&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zgDJWV88yhT1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(267,871&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20240930_zstWEtgVhTW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;30,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssetsAmortization_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(2,501&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;1,208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20240930_zV63y7omnRB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;28,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z0seNwLfOzX5" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;159,330,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(47,614,729&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;6,455,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zCqyoygGAXK9" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;118,171,345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20240930_zgT6NJvfvRQ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;159,330,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(47,614,729&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;6,455,913&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20240930_zVjQQ2nIRhpd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;118,171,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AD_ziL6RpkOCuuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Expected future amortization expense is as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z7015pVDNrhb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8BF_zR0mxwIrBxth" style="display: none"&gt;Schedule of expected future amortization expense&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years ended&#160;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 43%; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20240930_pp0p0" style="width: 43%; text-align: right" title="2025"&gt;7,189&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20240930_pp0p0" style="text-align: right" title="2026"&gt;7,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center"&gt;2027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c20240930_pp0p0" style="text-align: right" title="2027"&gt;7,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c20240930_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2028"&gt;7,187&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: #CCEEFF; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: #CCEEFF; text-align: center"&gt;&lt;span style="font-size: 10pt; color: #CCEEFF"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: #CCEEFF; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_c20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;28,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p id="xdx_8AE_zImLtawO1OF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="From2024-02-122024-02-13"
      decimals="0"
      id="Fact000608"
      unitRef="USD">159464039</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000610"
      unitRef="USD">47614729</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000612">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zX9HuSc029Bi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;span id="xdx_8BB_zEliGgyEuYck" style="display: none"&gt;Schedule of definite-life and indefinite-life intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJLKtksSICy6" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGwZpO5MmZE5" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;284,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0618"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NetDefinitelifeIntangibleAssetsAmortization_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0620"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0622"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;11,644&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1otNi1LCG0i" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending"&gt;296,621&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zi6qMQiBQoY5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(254,934&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(2,501&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(10,436&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zgDJWV88yhT1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(267,871&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20240930_zstWEtgVhTW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;30,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssetsAmortization_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(2,501&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;1,208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20240930_zV63y7omnRB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;28,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z0seNwLfOzX5" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;159,330,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(47,614,729&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;6,455,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zCqyoygGAXK9" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;118,171,345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20240930_zgT6NJvfvRQ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;159,330,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(47,614,729&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_c20240701__20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;6,455,913&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20240930_zVjQQ2nIRhpd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;118,171,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-09-30_us-gaap_PatentsMember"
      id="Fact000614">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000616"
      unitRef="USD">284977</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-012024-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000624"
      unitRef="USD">11644</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000626"
      unitRef="USD">296621</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000628"
      unitRef="USD">-254934</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2024-07-012024-09-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000632"
      unitRef="USD">-2501</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-012024-09-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000636"
      unitRef="USD">-10436</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-09-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000638"
      unitRef="USD">-267871</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000640"
      unitRef="USD">30043</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000644"
      unitRef="USD">-2501</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000648"
      unitRef="USD">1208</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000650"
      unitRef="USD">28750</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000652"
      unitRef="USD">159330161</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2024-07-012024-09-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000658"
      unitRef="USD">-47614729</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-012024-09-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000660"
      unitRef="USD">6455913</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-09-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000662"
      unitRef="USD">118171345</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000664"
      unitRef="USD">159330161</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000670"
      unitRef="USD">-47614729</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000672"
      unitRef="USD">6455913</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000674"
      unitRef="USD">118171345</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000676">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z7015pVDNrhb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8BF_zR0mxwIrBxth" style="display: none"&gt;Schedule of expected future amortization expense&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years ended&#160;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 43%; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20240930_pp0p0" style="width: 43%; text-align: right" title="2025"&gt;7,189&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20240930_pp0p0" style="text-align: right" title="2026"&gt;7,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center"&gt;2027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c20240930_pp0p0" style="text-align: right" title="2027"&gt;7,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c20240930_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2028"&gt;7,187&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: #CCEEFF; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: #CCEEFF; text-align: center"&gt;&lt;span style="font-size: 10pt; color: #CCEEFF"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: #CCEEFF; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_c20240930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;28,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;/p&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000678"
      unitRef="USD">7189</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000680"
      unitRef="USD">7187</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000682"
      unitRef="USD">7187</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000684"
      unitRef="USD">7187</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000686"
      unitRef="USD">28750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000688">&lt;p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zeKr5s7a5xJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_828_zZG8Uxb2weGk"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Convertible Notes Payable &#x2014;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;The January 2024 Note &#x2014;&lt;/i&gt;&lt;/b&gt;
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20240112__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_pp0p0" title="Principal amount"&gt;125,000&lt;/span&gt; (the &#x201c;January 2024 Note&#x201d;). The Company received a total of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_pp0p0" title="Gross proceeds"&gt;125,000&lt;/span&gt; in gross proceeds.&#160;The
January 2024 Note bears an interest rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_zIAQ17s0Z5u" title="Interest rate"&gt;12%&lt;/span&gt; per annum and shall mature on &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember" title="Maturity date"&gt;December 29, 2024&lt;/span&gt;. The Company is required to pay interest
quarterly, in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January
2024 Note. The January 2024 Note is convertible either at the option of the holder or automatically upon maturity into shares of the Company&#x2019;s
Common Stock at the Note Conversion Price of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20240112__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_pdd" title="Conversion price"&gt;3.38&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;December 2023 Notes &#x2014;
&lt;/i&gt;&lt;/b&gt;On December 20, 2023, the Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate
principal amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20231220__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_pp0p0" title="Principal amount"&gt;120,000&lt;/span&gt; (the &#x201c;December 2023 Notes&#x201d;). The Company received a total of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231220__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_pp0p0" title="Gross proceeds"&gt;120,000&lt;/span&gt; from the private placement
between December 2023 and January 2024.&#160;&lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_dp_c20231201__20231220__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_ztR2f2zTzSj5" title="Description of maturity date"&gt;The December 2023 Notes bear an interest rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20231201__20231220__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_zne1uffaWHYf" title="Interest rate"&gt;12%&lt;/span&gt; per annum and shall mature one year
after their respective dates of issuance (the &#x201c;Maturity Date&#x201d;).&lt;/span&gt; The Company is required to pay interest quarterly, in arrears,
in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest may accrue on the December Notes on a quarterly basis. The December 2023
Notes are convertible into shares of the Company&#x2019;s Common Stock in whole or in part at any time and from time to time, after the
original issue date and prior to the Maturity Date, at a conversion price of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20231220__us-gaap--DebtInstrumentAxis__custom--January2024NoteMember_pdd" title="Conversion price"&gt;3.38&lt;/span&gt; per share.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The January 2024 Note and December
2023 Notes balance at September 30, 2024 was $&lt;span id="xdx_907_ecustom--InterestExpenseRelatedToNoteBalance_c20240701__20240930_z8iK1fnEkTQe" title="Interest expense related to note balance"&gt;245,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Notes Payable &lt;/b&gt;&#x2014;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Bridge Loans &#x2014; &lt;/i&gt;&lt;/b&gt;On
September 16, 2024, the Company entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#x201c;RS Bio&#x201d;),
to issue a Promissory Note for the principal amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20240916__us-gaap--DebtInstrumentAxis__custom--September2024NoteMember_pp0p0" title="Principal amount"&gt;100,000&lt;/span&gt; (the &#x201c;September 2024 Note&#x201d;). The Company received $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfDebt_c20240901__20240916__us-gaap--DebtInstrumentAxis__custom--September2024NoteMember_pp0p0" title="Gross proceeds"&gt;100,000&lt;/span&gt;
in gross proceeds. The note bears an interest rate of &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20240901__20240916__us-gaap--DebtInstrumentAxis__custom--September2024NoteMember_zSeC3LjW0ho1" title="Interest rate"&gt;12%&lt;/span&gt; per annum and matures on &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20240901__20240916__us-gaap--DebtInstrumentAxis__custom--September2024NoteMember" title="Maturity date"&gt;December 31, 2024&lt;/span&gt;. The note balance at September 30,
2024 was $&lt;span id="xdx_906_eus-gaap--DebtConversionOriginalDebtAmount1_c20240901__20240916__us-gaap--DebtInstrumentAxis__custom--September2024NoteMember_pp0p0" title="Note balance"&gt;100,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On September 6, 2024, the Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;), to issue a Promissory
Note for the principal amount of &#x20ac;&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240906__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PasecoApSMember_zlMttqekgWfi" title="Principal amount"&gt;50,000&lt;/span&gt;. The note bears an interest rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20240901__20240906__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PasecoApSMember_zwTA30GiNxA4" title="Interest rate"&gt;12%&lt;/span&gt; per annum and matures on &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20240901__20240906__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PasecoApSMember_zTfbK9Uyin58" title="Maturity date"&gt;December 31, 2024&lt;/span&gt;. The
note balance at September 30, 2024 was approximately $&lt;span id="xdx_902_eus-gaap--DebtConversionOriginalDebtAmount1_c20240901__20240906__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PasecoApSMember_zWVZE5ZliIkb" title="Note balance"&gt;57,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20240205__us-gaap--DebtInstrumentAxis__custom--February2024NoteMember_pp0p0" title="Principal amount"&gt;105,263&lt;/span&gt;
(the &#x201c;February 2024 Note&#x201d;). The Company received $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20240201__20240205__us-gaap--DebtInstrumentAxis__custom--February2024NoteMember_pp0p0" title="Gross proceeds"&gt;100,000&lt;/span&gt; in gross proceeds after taking into account the &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20240205__us-gaap--DebtInstrumentAxis__custom--RSBioMember_z2cJjb0zLAK6" title="Original issue discount, percentage"&gt;5%&lt;/span&gt; original issue
discount. The note bears an interest rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20240201__20240205__us-gaap--DebtInstrumentAxis__custom--February2024NoteMember_zxOKndOxevY1" title="Interest rate"&gt;12%&lt;/span&gt; per annum and matures on &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20240201__20240205__us-gaap--DebtInstrumentAxis__custom--February2024NoteMember" title="Maturity date"&gt;December 31, 2024&lt;/span&gt;. The note balance, net of discount at September
30, 2024 was $&lt;span id="xdx_906_eus-gaap--DebtConversionOriginalDebtAmount1_c20240201__20240205__us-gaap--DebtInstrumentAxis__custom--February2024NoteMember_pp0p0" title="Note balance"&gt;105,263&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matures on December 31, 2024. The note balance, net of discount at September 30, 2024 was $526,315.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RSBioMember_zN38yFXBeBif" title="Principal amount"&gt;1,000,000&lt;/span&gt;. The
Company received a total of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfDebt_c20241101__20241103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RSBioMember_zvlediyJdajd" title="Gross proceeds"&gt;950,000&lt;/span&gt; in gross proceeds after taking into account the &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20231103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RSBioMember_zYp0N2kjIGGh" title="Original issue discount, percentage"&gt;5%&lt;/span&gt; original issue discount.&#160;The discount of
$&lt;span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20231103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RSBioMember_za6pp0tmeSi7" title="Debt discount"&gt;50,000&lt;/span&gt; will be accreted over the life of the note. The note bears an interest rate of &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20241101__20241103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RSBioMember_zUgQIdu0FTqg" title="Interest rate"&gt;12%&lt;/span&gt; per annum and matures on December 31, 2024.
The note balance, net of discount at September 30, 2024 was $&lt;span id="xdx_90C_eus-gaap--DebtConversionOriginalDebtAmount1_c20241101__20241103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RSBioMember_zDTPIPX7QlJd" title="Note balance"&gt;750,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Promissory Note &#x2014; &lt;/b&gt;On
March 30, 2020 (the &#x201c;Issuance Date&#x201d;), the Company issued a Promissory Note in the principal amount of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20200330__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pp0p0" title="Principal amount"&gt;5,000,000&lt;/span&gt; (the &#x201c;Promissory
Note&#x201d;) to Paseco ApS. There have been eight amendments to the Promissory Note since the issuance date, the most recent of which
is dated August 1, 2024. The principal amount of the Promissory Note, as amended, was payable on &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20200301__20200330__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zQz8VJK7L8Gj" title="Maturity date"&gt;November 1, 2024&lt;/span&gt; (the &#x201c;Maturity
Date&#x201d;). The Promissory Note, as amended, bears interest at a fixed rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200301__20200330__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zkZsptKPTFuj" title="Interest rate"&gt;12%&lt;/span&gt; per annum. The Promissory Note balance, net of discount
at September 30, 2024 is $&lt;span id="xdx_902_eus-gaap--DebtConversionOriginalDebtAmount1_c20200301__20200330__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pp0p0" title="Note balance"&gt;823,182&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company&#x2019;s obligations
under the Promissory Note, November 2023 Note, January 2024 Note, February 2024 Note and the September 2024 Note are secured by a Security
Agreement. To secure the Company&#x2019;s obligations under the Promissory Note, the Company entered into a Security Agreement with the
Holder, pursuant to which the Company granted a lien on all assets of the Company (the &#x201c;Collateral&#x201d;) for the benefit of Paseco
ApS. Upon an Event of Default (as defined in the notes, respectively) Paseco ApS may, among other things, collect or take possession of
the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral.&lt;/p&gt;









</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-12_custom_January2024NoteMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-07-012024-09-30_custom_January2024NoteMember"
      decimals="0"
      id="Fact000692"
      unitRef="USD">125000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-07-012024-09-30_custom_January2024NoteMember"
      decimals="INF"
      id="Fact000694"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-07-012024-09-30_custom_January2024NoteMember"
      id="Fact000696">2024-12-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-01-12_custom_January2024NoteMember"
      decimals="INF"
      id="Fact000698"
      unitRef="USDPShares">3.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-20_custom_January2024NoteMember"
      decimals="0"
      id="Fact000702"
      unitRef="USD">120000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-12-012023-12-20_custom_January2024NoteMember"
      decimals="0"
      id="Fact000704"
      unitRef="USD">120000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-12-012023-12-20_custom_January2024NoteMember"
      id="Fact000706">The December 2023 Notes bear an interest rate of 12% per annum and shall mature one year
after their respective dates of issuance (the &#x201c;Maturity Date&#x201d;).</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-12-012023-12-20_custom_January2024NoteMember"
      decimals="INF"
      id="Fact000708"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-20_custom_January2024NoteMember"
      decimals="INF"
      id="Fact000710"
      unitRef="USDPShares">3.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <RENB:InterestExpenseRelatedToNoteBalance
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000712"
      unitRef="USD">245000</RENB:InterestExpenseRelatedToNoteBalance>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-09-16_custom_September2024NoteMember"
      decimals="0"
      id="Fact000714"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-09-012024-09-16_custom_September2024NoteMember"
      decimals="0"
      id="Fact000716"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-09-012024-09-16_custom_September2024NoteMember"
      decimals="INF"
      id="Fact000718"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-09-012024-09-16_custom_September2024NoteMember"
      id="Fact000720">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2024-09-012024-09-16_custom_September2024NoteMember"
      decimals="0"
      id="Fact000722"
      unitRef="USD">100000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-09-06_custom_PasecoApSMember"
      decimals="0"
      id="Fact000724"
      unitRef="USD">50000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-09-012024-09-06_custom_PasecoApSMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-09-012024-09-06_custom_PasecoApSMember"
      id="Fact000728">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2024-09-012024-09-06_custom_PasecoApSMember"
      decimals="0"
      id="Fact000730"
      unitRef="USD">57000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-02-05_custom_February2024NoteMember"
      decimals="0"
      id="Fact000732"
      unitRef="USD">105263</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-02-012024-02-05_custom_February2024NoteMember"
      decimals="0"
      id="Fact000734"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-02-05_custom_RSBioMember"
      decimals="INF"
      id="Fact000736"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-02-012024-02-05_custom_February2024NoteMember"
      decimals="INF"
      id="Fact000738"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-02-012024-02-05_custom_February2024NoteMember"
      id="Fact000740">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2024-02-012024-02-05_custom_February2024NoteMember"
      decimals="0"
      id="Fact000742"
      unitRef="USD">105263</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-03_custom_RSBioMember"
      decimals="0"
      id="Fact000744"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-11-012024-11-03_custom_RSBioMember"
      decimals="0"
      id="Fact000746"
      unitRef="USD">950000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-11-03_custom_RSBioMember"
      decimals="INF"
      id="Fact000748"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-11-03_custom_RSBioMember"
      decimals="0"
      id="Fact000750"
      unitRef="USD">50000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-11-012024-11-03_custom_RSBioMember"
      decimals="INF"
      id="Fact000752"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2024-11-012024-11-03_custom_RSBioMember"
      decimals="0"
      id="Fact000754"
      unitRef="USD">750000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-03-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact000756"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2020-03-012020-03-30_custom_PromissoryNoteMember"
      id="Fact000758">2024-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-03-012020-03-30_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact000760"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2020-03-012020-03-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact000762"
      unitRef="USD">823182</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000767">&lt;p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3uwYr8T02Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_82A_zxDTFvTbQTEi"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Purchase Agreement with Lincoln Park Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On June
20, 2023, the Company entered into a purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC
(&#x201c;Lincoln Park&#x201d;), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase,
up to $&lt;span id="xdx_901_eus-gaap--PurchaseObligation_c20240620__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member_pp0p0" title="Obligation to purchase"&gt;20,000,000&lt;/span&gt; of shares of Common Stock over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the
2023 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed
to provide Lincoln Park with certain registration rights related to the shares issued under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;In consideration for entering into
the 2023 Purchase Agreement, the Company issued &lt;span id="xdx_902_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_ztxKjaqn7Bn5" title="Number of shares issued"&gt;696,021&lt;/span&gt; shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the quarter ended September
30, 2024 and 2023, no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Common Stock Issuances &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On June
14, 2024, Renovaro Inc., a Delaware corporation (the &#x201c;&lt;span style="text-decoration: underline"&gt;Company&lt;/span&gt;&#x201d;) closed a private
placement of&#160;&lt;span id="xdx_903_eus-gaap--PartnersCapitalAccountUnitsSoldInPrivatePlacement_c20240601__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Closed private placement units"&gt;5,315,215&lt;/span&gt;&#160;of the Company&#x2019;s units, each such Unit consisting of (i) one share of the Company&#x2019;s Common
Stock and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain investors (the &#x201c;June
2024 Private Placement&#x201d;).&#160;Related to the June 2024 Private Placement, ranging from July 3, 2024, to September 16, 2024, the
Company sold &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240703__20240916__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Sale of private placement units"&gt;1,423,456&lt;/span&gt; Units at a price per Unit equal to $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_c20240916__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Sale of units, per value"&gt;1.4726&lt;/span&gt; to a certain investor who paid in cash an aggregate amount of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240703__20240916__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp0p0" title="Consideration amount"&gt;2,096&lt;/span&gt;,181
in consideration of the Units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 1, 2024, the Company
issued&#160;&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesIssuedForConsultingServices_c20240730__20240802__us-gaap--AwardTypeAxis__custom--CommonStockIssuancesMember_zgVFPZAW8WO3" title="Issuance of common stock shares"&gt;2,000,000&lt;/span&gt;&#160;shares of Common Stock for consulting services valued at $&lt;span id="xdx_904_ecustom--StockIssuedDuringPeriodValueIssuedForConsultingServices_c20240730__20240802__us-gaap--AwardTypeAxis__custom--CommonStockIssuancesMember_zALMdIgj94l1" title="Common stock for consulting services value"&gt;1,400,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Stock-based Compensation &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company recognizes compensation
costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated
on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of
the stock options granted using the Black-Scholes option-pricing model are as follows in the three months ended September 30, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLe9lE4PEy6j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zWZMFDUVA2Ac" style="display: none"&gt;Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Renovaro Inc.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20240930__dei--LegalEntityAxis__custom--RenovaroMember_z65XOiGLPiC1" title="Expected term (in years)"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20240930__dei--LegalEntityAxis__custom--RenovaroMember_zsgHLUPoP8Ek" title="Volatility"&gt;113.12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20240930__dei--LegalEntityAxis__custom--RenovaroMember_z9NbtsZBZttg" title="Risk free interest rate"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20240930__dei--LegalEntityAxis__custom--RenovaroMember_z9GtZViQPjKg" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 23, 2024, Avram Miller,
a former member of the Company&#x2019;s board of directors (the &#x201c;Board of Directors&#x201d;), forfeited &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20240801__20240823__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_pdd" title="Shares forfeited"&gt;833,333&lt;/span&gt; shares of Common Stock
from the original &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20231001__20231011__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_pdd" title="Shares forfeited"&gt;1,000,000&lt;/span&gt; shares of Common Stock for advisory services originally granted to him on October 11, 2023. As consideration
for such forfeiture, the Company granted to Mr. Miller, an option to purchase &lt;span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodShares_c20240801__20240823__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_pdd" title="Purchase of stock"&gt;978,261&lt;/span&gt; shares of Common Stock of the Company with a per-share
exercise price of, $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240823__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_pdd" title="Exercise price"&gt;0.69&lt;/span&gt;. The Company determined that this transaction represented a modification of the original award. The Company measured
the fair value of the options issued as compared to the fair value of the original issuance and determined that there was no incremental
compensation to recognize as the fair value of the options was less than the fair value of the Common Stock. Therefore, the Company will
recognize the remaining fair value of the original award over the remaining vesting period, which is one year. &#160;The Company recognized
stock-based compensation expense of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20240701__20240930__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_pp0p0" title="Stock based compensation expense"&gt;222,306&lt;/span&gt; related to the vesting of the stocks options during the period ended September 30, 2024.
At September 30, 2024, the Company had $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20240930__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_pp0p0" title="Unrecognized compensation cost"&gt;1,122,537&lt;/span&gt; of unrecognized compensation cost related to the options which vest at August 23, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In total, the Company recognized
stock-based compensation expense related to options of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_c20240701__20240930_zXCTq5hxQvi2" title="Stock based compensation expense"&gt;357,648&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20230701__20230930_zS1MesIOUeq3" title="Stock based compensation expense"&gt;983,829&lt;/span&gt; for the three months ended September 30, 2024 and 2023, respectively.
At September 30, 2024, the Company had approximately $&lt;span id="xdx_903_ecustom--EmployeeServiceShareBasedCompensationNonvestedAwardTotalCompensationCostNotYetRecognized_iI_pp0p0_c20240930_zn66f8Rh6XNi" title="Unrecognized compensation cost related to non-vested options"&gt;&lt;span id="xdx_904_ecustom--EmployeeServiceShareBasedCompensationNonvestedAwardTotalCompensationCostNotYetRecognized_c20240930_pp0p0" title="Unrecognized compensation cost related to non-vested options"&gt;1,239,528&lt;/span&gt;&lt;/span&gt; of unrecognized compensation cost related to non-vested options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2024-06-20_custom_PurchaseAgreement2023Member"
      decimals="0"
      id="Fact000769"
      unitRef="USD">20000000</us-gaap:PurchaseObligation>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-20_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000771"
      unitRef="Shares">696021</us-gaap:SharesIssued>
    <us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement
      contextRef="From2024-06-012024-06-14_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000773"
      unitRef="Shares">5315215</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-07-032024-09-16_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000775"
      unitRef="Shares">1423456</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-09-16_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000777"
      unitRef="USDPShares">1.4726</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-07-032024-09-16_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000779"
      unitRef="USD">2096</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <RENB:StockIssuedDuringPeriodSharesIssuedForConsultingServices
      contextRef="From2024-07-302024-08-02_custom_CommonStockIssuancesMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">2000000</RENB:StockIssuedDuringPeriodSharesIssuedForConsultingServices>
    <RENB:StockIssuedDuringPeriodValueIssuedForConsultingServices
      contextRef="From2024-07-302024-08-02_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact000783"
      unitRef="USD">1400000</RENB:StockIssuedDuringPeriodValueIssuedForConsultingServices>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000785">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLe9lE4PEy6j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zWZMFDUVA2Ac" style="display: none"&gt;Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Renovaro Inc.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20240930__dei--LegalEntityAxis__custom--RenovaroMember_z65XOiGLPiC1" title="Expected term (in years)"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20240930__dei--LegalEntityAxis__custom--RenovaroMember_zsgHLUPoP8Ek" title="Volatility"&gt;113.12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20240930__dei--LegalEntityAxis__custom--RenovaroMember_z9NbtsZBZttg" title="Risk free interest rate"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20240930__dei--LegalEntityAxis__custom--RenovaroMember_z9GtZViQPjKg" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-07-012024-09-30_custom_RenovaroMember"
      id="Fact000787">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012024-09-30_custom_RenovaroMember"
      decimals="INF"
      id="Fact000789"
      unitRef="Pure">1.1312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012024-09-30_custom_RenovaroMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-07-012024-09-30_custom_RenovaroMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="From2024-08-012024-08-23_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Shares">833333</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="From2023-10-012023-10-11_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-08-012024-08-23_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">978261</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-23_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact000801"
      unitRef="USDPShares">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="0"
      id="Fact000803"
      unitRef="USD">222306</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-09-30_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="0"
      id="Fact000805"
      unitRef="USD">1122537</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000809"
      unitRef="USD">357648</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000811"
      unitRef="USD">983829</us-gaap:ShareBasedCompensation>
    <RENB:EmployeeServiceShareBasedCompensationNonvestedAwardTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000813"
      unitRef="USD">1239528</RENB:EmployeeServiceShareBasedCompensationNonvestedAwardTotalCompensationCostNotYetRecognized>
    <RENB:EmployeeServiceShareBasedCompensationNonvestedAwardTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000815"
      unitRef="USD">1239528</RENB:EmployeeServiceShareBasedCompensationNonvestedAwardTotalCompensationCostNotYetRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000817">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zqd0lxgJxxJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_825_zvVDvlZXdzNd"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 31, 2020, the Company entered into a Statement of Work and License
Agreement (the &#x201c;HBV License Agreement&#x201d;) by and among the Company, G Tech Bio, LLC, a California limited liability company
(&#x201c;G Tech&#x201d;), and G Health Research Foundation, a not-for-profit entity organized under the laws of California doing business
as Seraph Research Institute (&#x201c;SRI&#x201d;) (collectively the &#x201c;Licensors&#x201d;), whereby the Company acquired a perpetual,
sublicensable, exclusive license (the &#x201c;HBV License&#x201d;) for a treatment under development (the &#x201c;Treatment&#x201d;) aimed
to treat Hepatitis B Virus (HBV) infections.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24-month period, and provides for an up-front payment of $&lt;span id="xdx_906_eus-gaap--PaymentsForFees_pn5n6_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z9mB8O2P3262" title="Payment for license"&gt;1.2&lt;/span&gt; million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a &lt;span id="xdx_902_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zzLnzSRQUcAc" title="Royalty percentage"&gt;2%&lt;/span&gt; royalty to G Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $&lt;span id="xdx_90F_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zUd8n3QAIv2a" title="Payment for license"&gt;1.2&lt;/span&gt; million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement during the quarters ending September 30, 2024, and 2023.
The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies
sub-section below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#x201c;License Development Agreement&#x201d;), by and among the Company, G
Tech and SRI (collectively, the &#x201c;Licensors&#x201d;), whereby the Company acquired a perpetual sublicensable, exclusive license (the
&#x201c;Development License&#x201d;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating
pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19
and pan-influenza (the &#x201c;Prevention and Treatment&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the Development License Agreement
provides for an up-front payment of $&lt;span id="xdx_902_ecustom--UpfrontPayment_pp0p0_c20191114__20191115_zOCrzeqCKDJ3" title="Up-front payment"&gt;10,000,000&lt;/span&gt; and a $&lt;span id="xdx_90A_ecustom--PaymentForExpenditures_pp0p0_c20191114__20191115_zTpEMCgThz75" title="Payment for expenditures"&gt;760,000&lt;/span&gt; payment for expenditures to date prior to the effective date related to
research towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement,
in each case subject to the terms of the Development License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Development License Agreement
provides for (i) cooperation related to the development of intellectual property related to the Prevention and Treatment and (ii) a 3%
royalty to G Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product
candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this
license (see Contingencies below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#x201c;ALC License Agreement&#x201d;) with Serhat
G&#xfc;mr&#xfc;kc&#xfc; and SRI (collectively, the &#x201c;Licensors&#x201d;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of &lt;span id="xdx_909_ecustom--InitialPayment_pp0p0_c20210824__20210825_zOdfRHLepJP5" title="Initial payment"&gt;$600,000&lt;/span&gt; and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of &lt;span id="xdx_90B_ecustom--InitialPayment_pp0p0_c20210909__20210910_zxnD6e2Rmf6c" title="Initial payment"&gt;$600,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;G Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Service Agreements&lt;/b&gt; &lt;i&gt;&#x2013;&lt;/i&gt;The
Company maintains employment agreements with certain senior staff in the ordinary course of business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;Securities Class Action Litigation. &lt;/i&gt;On July 26,
2022 and July 28, 2022, securities class action complaints (the former, the &#x201c;Chow Action&#x201d; and the latter, the &#x201c;Manici
Action&#x201d;) and together, the &#x201c;Securities Class Action Litigation&#x201d;) were filed by purported stockholders of the Company
in the United States District Court for the Central District of California against the Company and certain of the Company&#x2019;s current
and former officers and directors. The complaints allege, among other things, that the defendants violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of
material fact in connection with the Company&#x2019;s relationship with Serhat G&#xfc;mr&#xfc;kc&#xfc; and its commercial prospects. The
complaints seek unspecified damages, interest, fees, and costs. On November 22, 2022, the Manici Action was voluntarily dismissed without
prejudice, but the Chow action remains pending.&#160;On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The
lead plaintiff filed an amended complaint on December 15, 2023. The Company has filed a motion to dismiss the amended complaint on March
15, 2024. The Court denied the Company&#x2019;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which
the parties signed a stipulation of settlement, dated November 8, 2024.&#160; The plaintiff&#x2019;s deadline to file a motion for preliminary
approval of the settlement is December 9, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;Federal Derivative Litigation&lt;/i&gt;. On September 22,
2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District of California.
On January 19, 2023, John Solak filed a substantially similar shareholder derivative action in the United States District Court for the
District of Delaware. Both derivative actions recite similar underlying facts as those alleged in the Securities Class Action Litigation.
The actions, filed on behalf of the Company, name Serhat G&#xfc;mr&#xfc;kc&#xfc; and certain of the Company&#x2019;s former directors as
defendants. The actions also name the Company as a nominal defendant. The actions allege violations of Sections 14(a) and 20(a) of the
Securities Exchange Act of 1934 and also set out claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting,
and gross mismanagement. Plaintiffs do not quantify any alleged injury, but seek damages, disgorgement, restitution, and other costs and
expenses. On January 24, 2023, the United States District Court for the Central District of California stayed the Koenig matter pending
resolution of the defendants&#x2019; anticipated motion to dismiss in the Securities Class Action Litigation. On April 4, 2023, the United
States District Court for the District of Delaware stayed the Solak matter pending resolution of the defendants&#x2019; anticipated motion
to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California
denied defendants&#x2019; motion to dismiss the Securities Class Action Litigation. On October 23, 2024, the court in the Koenig matter
stayed the case pending further order of the court.&#160; The parties&#x2019; deadline to file a joint status report in the Koenig matter
is January 10, 2025.&#160; On October 28, 2024, the court in the Solak matter stayed the case for ninety (90) days.&#160; The defendants
have not yet responded to either complaint. The Company intends to contest these matters but expresses no opinion as to the likelihood
of favorable outcomes. Management is unable to determine the likelihood of a loss, including a possible range of losses, if any, arising
from this matter as of the reporting date.&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;State Derivative Litigation. On October 20, 2022, Susan
Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County, reciting similar underlying facts
as those alleged in the Securities Class Action Litigation. The action, filed on behalf of the Company, names Serhat G&#xfc;mr&#xfc;kc&#xfc;
and certain of the Company&#x2019;s current and former directors as defendants. The action also names the Company as a nominal defendant.
The action sets out claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement.
Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January
20, 2023, the Court stayed the Midler matter pending resolution of the defendants&#x2019; anticipated motion to dismiss in the Securities
Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#x2019;
motion to dismiss the Securities Class Action Litigation. On October 28, 2024, the court in the Midler matter stayed the case for ninety
(90) days. The defendants have not yet responded to the complaint. The Company intends to contest this matter but expresses no opinion
as to the likelihood of a favorable outcome. Management is unable to determine the likelihood of a loss, including a possible range of
losses, if any, arising from this matter as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#xfc;mr&#xfc;kc&#xfc;, William Anderson Wittekind (&#x201c;Wittekind&#x201d;), G Tech, SG &amp;amp; AW Holdings, LLC, and SRI (collectively,
the &#x201c;Defendants&#x201d;). The Complaint alleges that the Defendants engaged in a &#x201c;concerted, deliberate scheme to alter, falsify,
and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza pipelines.&#x201d;
Specifically, &#x201c;Defendants manipulated negative results to reflect positive outcomes from various studies, and even fabricated studies
out of whole cloth.&#x201d; As a result of the Defendants&#x2019; conduct, the Company claims that it &#x201c;paid approximately $25 million
to Defendants and third-parties that it would not otherwise have paid.&#x201d; On April 21, 2023, defendants Wittekind, G Tech, SG &amp;amp;
AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#x2019;s claims, as well as a motion to strike.
On September 6, 2023, the court denied in part and granted in part the pending motions. On September 7, 2023, the court entered a case
management order setting the final status conference, trial, and other intervening deadlines.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On December
4, 2023, the Defendants answered the Company&#x2019;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, &lt;i&gt;inter
alia&lt;/i&gt;, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp;amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial is currently scheduled
to begin on March 3, 2025. The Company denies these allegations and intends to vigorously defend against the cross claims while pursuing
its claims against the Defendants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On March 1, 2021, the Company&#x2019;s
former Chief Financial Officer, Robert Wolfe, and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the
District of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe
and Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable
cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The
allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior
Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company&#x2019;s motion to dismiss, dismissing the abuse
of process claim against all defendants and all claims against Mark Dybul and Henrik Gr&#xf8;nfeldt-S&#xf8;rensen, the Company&#x2019;s
former Chief Executive Officer and former member of the Board of Directors, respectively. On November 29, 2022, the Company filed a motion
for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24, 2023, the court denied the motion
for summary judgment.On November 7, 2024, the Court reset the trial date for May 6, 2025. The Company denies the allegations set forth
in the Complaint and will continue to vigorously defend against the remaining claim.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On June 7, 2023, Weird Science
LLC (&#x201c;Weird Science&#x201d;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity
Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#x201c;Trusts&#x201d;) (collectively,
&#x201c;Plaintiffs&#x201d;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified Complaint,
Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science, and RS
Group ApS (the &#x201c;Investor Rights Agreement&#x201d;). According to the Verified Complaint, the Investor Rights Agreement required the
Company to (i) notify all &#x201c;Holders&#x201d; of &#x201c;Registrable Securities&#x201d; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#x201c;FAC&#x201d;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#x2019; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and a hearing is scheduled for November 15, 2024. The Company denies Plaintiffs&#x2019; allegations and intends
to vigorously defend against the claims.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 24, 2023, counsel on
behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company&#x2019;s
books and records (the &#x201c;Demand&#x201d;) pursuant to Delaware General Corporation Law, &#xa7; 220 (&#x201c;Section 220&#x201d;). The
Demand seeks the Company&#x2019;s books and records in connection with various issues identified in the Demand. The Company takes its obligations
under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with those obligations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#x201c;Special
Committee&#x201d;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp;amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters. The Special Committee&#x2019;s investigation is ongoing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 23, 2024, Weird Science
and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against
certain officers, directors, and investors of the Company, as well as other defendants, in connection with, &lt;i&gt;inter alia&lt;/i&gt;, Weird Science
and Wittekind&#x2019;s demand for corrective action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified
Stockholder Derivative Complaint (&#x201c;Derivative Complaint&#x201d;) alleges, among other claims, violations of Section 13(d) and 14(a)
and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary
duty, corporate waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory,
exemplary, and punitive damages and certain injunctive relief. The Derivative Complaint names the Company as a nominal defendant. On July
19, 2024, certain of the director defendants, who had agreed to waive service of the summons and Derivative Complaint, filed a motion
to dismiss the Derivative Complaint on a variety of procedural and substantive grounds. A hearing on the motion dismiss was held on October
3, 2024 and the court subsequently took the motion under submission. On October 22, 2024, the plaintiffs filed a notice of certain subsequent
events that they allege relate to their pending motion to dismiss. On October 29, 2024, the court granted the director defendants&#x2019;
motion to dismiss and dismissed the Derivative Complaint without prejudice, but also without leave to amend.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On June 21, 2024, the Company filed
suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company and two
companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, &lt;i&gt;inter alia&lt;/i&gt;, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForFees
      contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact000819"
      unitRef="USD">1200000</us-gaap:PaymentsForFees>
    <RENB:RoyaltyPercentage
      contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact000821"
      unitRef="Pure">0.02</RENB:RoyaltyPercentage>
    <us-gaap:PaymentsForFees
      contextRef="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact000823"
      unitRef="USD">1200000</us-gaap:PaymentsForFees>
    <RENB:UpfrontPayment
      contextRef="From2019-11-142019-11-15"
      decimals="0"
      id="Fact000825"
      unitRef="USD">10000000</RENB:UpfrontPayment>
    <RENB:PaymentForExpenditures
      contextRef="From2019-11-142019-11-15"
      decimals="0"
      id="Fact000827"
      unitRef="USD">760000</RENB:PaymentForExpenditures>
    <RENB:InitialPayment
      contextRef="From2021-08-242021-08-25"
      decimals="0"
      id="Fact000831"
      unitRef="USD">600000</RENB:InitialPayment>
    <RENB:InitialPayment
      contextRef="From2021-09-092021-09-10"
      decimals="0"
      id="Fact000833"
      unitRef="USD">600000</RENB:InitialPayment>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000839">&lt;p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zwcynqaslLxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9&#160;&#x2014;&#160;&lt;span id="xdx_826_zvphfTKLEydc"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;As of September 30, 2024, the Company
has accrued $&lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_zh2cXq2paYOi" title="Accrued balance"&gt;283,652&lt;/span&gt; of compensation related expenses for the Company&#x2019;s former Chief Executive Officer, Mark Dybul, related to budget
constraints.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 23, 2024, Avram Miller,
a former member of the Board of Directors, forfeited &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20240801__20240823__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zt0wRjrfPH1h" title="Shares forfeited"&gt;833,333&lt;/span&gt; shares of Common Stock from the original &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20231001__20231011__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zoIXn7oGSLFi" title="Shares forfeited"&gt;1,000,000&lt;/span&gt; shares of Common Stock
for advisory services originally granted to him on October 11, 2023. As consideration for such forfeiture, the Company granted to Mr.
Miller, an option to purchase &lt;span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_c20240801__20240823__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zdkN4j5GYQN1" title="Purchase of stock"&gt;978,261&lt;/span&gt; shares of Common Stock of the Company with a per-share exercise price of, $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240823__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_z2CqzLtaEmw" title="Exercise price"&gt;0.69&lt;/span&gt;. The Company determined
that this transaction represented a modification of the original award. The Company measured the fair value of the options issued as compared
to the fair value of the original issuance and determined that there was no incremental compensation to recognize as the fair value of
the options was less than the fair value of the Common Stock. Therefore, the Company will recognize the remaining fair value of the original
award over the remaining vesting period, which is one year. &#160;The Company recognized stock-based compensation expense of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_znXnjXs27rIe" title="Stock based compensation expense"&gt;222,306&lt;/span&gt;
related to the vesting of the stocks options during the period ended September 30, 2024. At September 30, 2024, the Company had $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20240930__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zifRmusWsvV2" title="Unrecognized compensation cost"&gt;1,122,537&lt;/span&gt;
of unrecognized compensation cost related to the options which vest at August 23, 2025.&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-07-012024-09-30_custom_MarkDybulMember"
      decimals="0"
      id="Fact000841"
      unitRef="USD">283652</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="From2024-08-012024-08-23_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Shares">833333</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="From2023-10-012023-10-11_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact000845"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-08-012024-08-23_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Shares">978261</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-23_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact000849"
      unitRef="USDPShares">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="0"
      id="Fact000851"
      unitRef="USD">222306</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-09-30_srt_BoardOfDirectorsChairmanMember_custom_AvramMillerMember"
      decimals="0"
      id="Fact000853"
      unitRef="USD">1122537</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000858">&lt;p id="xdx_806_eus-gaap--SegmentReportingDisclosureTextBlock_zOcVRgTHHyW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 &#x2014; &lt;span id="xdx_829_zKvtoVLG6Lbe"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;For the period ending September
30, 2024, the Company had two reportable segments. These segments have different strategic and economic goals and are managed separately
because they require different technology and marketing strategies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap; width: 13%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Reportable Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap; width: 86%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Description &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;RENB (United States)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;Developing new immunotherapies to combat cancer &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;RENC (Netherlands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The Company&#x2019;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the quarter ended September 30, 2024, there were no significant inter-company revenues or expenses. The chief operating decision
maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported
on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zOCU6KQym2fk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zFiS0lA7pq93" style="display: none"&gt;Schedule of segment operating loss and
    asset information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingIncomeLoss_c20240701__20240930__srt--StatementGeographicalAxis__country--US_zxwpK9GtxHEi" style="width: 12%; text-align: right" title="Operating income loss"&gt;4,960,737&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Assets_iI_c20240930__srt--StatementGeographicalAxis__country--US_z02Wd7i8DS7b" style="width: 12%; text-align: right" title="Assets"&gt;2,856,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20240701__20240930__srt--StatementGeographicalAxis__country--NL_z4bZWzKwTzL5" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss"&gt;48,377,817&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Assets_iI_c20240930__srt--StatementGeographicalAxis__country--NL_z4Zfpdcj9q13" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"&gt;118,976,311&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingIncomeLoss_iN_di_c20240701__20240930_zUqh07KoI6X4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss"&gt;53,338,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Assets_iI_c20240930_zj3SYbs1qXXc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets"&gt;121,832,637&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zv1sWFpELwyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#x2019;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#x2019;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;Information
regarding each reportable segment for the quarter ended September 30, 2024, is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zA1N4BhNG707" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zCqsLop11NLe" style="display: none"&gt;Schedule of information regarding segment reporting&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zd2xFOOgALP2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zbeKRWRXv49" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20240701__20240930_za9UaPKNLTee" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENB&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENC&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zvXJWCPkLS0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;4,548,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;752,802&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,301,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zoPqgr0geiil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;390,189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zv8Wbo47w5W5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,614,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,614,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_zPmuWzPwqLQd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,602&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,385&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_iN_di_zyQNIkPQPsf9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Segment operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;4,960,737&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;48,377,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;53,338,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zRXN90tTmiXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Geographic information:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;RENB and
RENC are managed on a worldwide basis but operate in offices located in the United Stated and the Netherlands, respectively. The geographic
information analyses the Company&#x2019;s operations and assets based on the country in which each segment operates. In presenting this
geographic information, segment operating results have been based on the geographic location in which the services were provided to the
segment and segment assets were based on the geographic location of the assets.&lt;/p&gt;









</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000860">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zOCU6KQym2fk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zFiS0lA7pq93" style="display: none"&gt;Schedule of segment operating loss and
    asset information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingIncomeLoss_c20240701__20240930__srt--StatementGeographicalAxis__country--US_zxwpK9GtxHEi" style="width: 12%; text-align: right" title="Operating income loss"&gt;4,960,737&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Assets_iI_c20240930__srt--StatementGeographicalAxis__country--US_z02Wd7i8DS7b" style="width: 12%; text-align: right" title="Assets"&gt;2,856,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20240701__20240930__srt--StatementGeographicalAxis__country--NL_z4bZWzKwTzL5" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss"&gt;48,377,817&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Assets_iI_c20240930__srt--StatementGeographicalAxis__country--NL_z4Zfpdcj9q13" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"&gt;118,976,311&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingIncomeLoss_iN_di_c20240701__20240930_zUqh07KoI6X4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss"&gt;53,338,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Assets_iI_c20240930_zj3SYbs1qXXc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets"&gt;121,832,637&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30_country_US"
      decimals="0"
      id="Fact000862"
      unitRef="USD">4960737</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30_country_US"
      decimals="0"
      id="Fact000864"
      unitRef="USD">2856326</us-gaap:Assets>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30_country_NL"
      decimals="0"
      id="Fact000866"
      unitRef="USD">48377817</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30_country_NL"
      decimals="0"
      id="Fact000868"
      unitRef="USD">118976311</us-gaap:Assets>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000870"
      unitRef="USD">-53338554</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000872"
      unitRef="USD">121832637</us-gaap:Assets>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000874">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zA1N4BhNG707" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zCqsLop11NLe" style="display: none"&gt;Schedule of information regarding segment reporting&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zd2xFOOgALP2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zbeKRWRXv49" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20240701__20240930_za9UaPKNLTee" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENB&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENC&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zvXJWCPkLS0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;4,548,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;752,802&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,301,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zoPqgr0geiil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;390,189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zv8Wbo47w5W5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,614,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,614,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_zPmuWzPwqLQd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,602&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,385&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_iN_di_zyQNIkPQPsf9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Segment operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;4,960,737&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;48,377,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;53,338,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">4548449</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000877"
      unitRef="USD">752802</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000878"
      unitRef="USD">5301251</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000880"
      unitRef="USD">381686</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000881"
      unitRef="USD">8503</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000882"
      unitRef="USD">390189</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-07-012024-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000884"
      unitRef="USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-07-012024-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000885"
      unitRef="USD">47614729</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000886"
      unitRef="USD">47614729</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012024-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000888"
      unitRef="USD">30602</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012024-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000889"
      unitRef="USD">1783</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000890"
      unitRef="USD">32385</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">-4960737</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000893"
      unitRef="USD">-48377817</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="Fact000894"
      unitRef="USD">-53338554</us-gaap:OperatingIncomeLoss>
    <us-gaap:AssetAcquisitionTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000899">&lt;p id="xdx_801_eus-gaap--AssetAcquisitionTextBlock_zrn2ZTxSUgmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 &#x2014; &lt;span id="xdx_824_zXI1UmmUR9q7"&gt;ACQUISITION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On September
28, 2023, the Company, entered into a Stock Purchase Agreement (the &#x201c;&lt;span style="text-decoration: underline"&gt;Purchase Agreement&lt;/span&gt;&#x201d;)
with GEDi Cube Intl Ltd., a private company formed under the laws of England and Wales (&#x201c;&lt;span style="text-decoration: underline"&gt;GEDi
Cube&lt;/span&gt;&#x201d;) to acquire 100% of the equity interests of GEDi Cube from its equity holders (the &#x201c;&lt;span style="text-decoration: underline"&gt;Sellers&lt;/span&gt;&#x201d;).
On September 28, 2023, the Board of Directors of the Company, and the board of managers of GEDi Cube unanimously approved the Purchase
Agreement and on January 25, 2024, the shareholders of the Company approved the issuance of the shares of Common Stock pursuant to the
Purchase Agreement. On February 13, 2024 (the &#x201c;Closing Date&#x201d;), the Company consummated the acquisition of GEDi Cube and the
other transactions contemplated by the Stock Purchase Agreement (collectively, the &#x201c;Transaction&#x201d;). As a result of the Transaction,
GEDi Cube became a wholly-owned subsidiary of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a &#x201c;GEDi Cube Share&#x201d; and, collectively, the &#x201c;GEDi Cube Shares&#x201d;)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller&#x2019;s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (&#x201c;Common Stock&#x201d;), which represents the 67,224,089
shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously issued to
a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director of
the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the &#x201c;Closing
Consideration&#x201d;) plus 5,610,100 shares of Common Stock representing the Seller&#x2019;s Earnout Shares (defined below) resulting from
the automatic conversion of the Company&#x2019;s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller&#x2019;s
pro rata percentage of the shares of Common Stock (the &#x201c;Earnout Shares&#x201d; and, together with the Closing Consideration, the
&#x201c;Exchange Consideration&#x201d;) to be issued to the Sellers upon the exercise or conversion of any of the Company&#x2019;s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the &#x201c;Closing Derivative Securities&#x201d;).
Each Seller&#x2019;s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
transaction was accounted for in accordance with the provisions of ASC 805-10 -&#160;&lt;i&gt;Business Combinations&lt;/i&gt;. &lt;/span&gt;As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The assets
acquired and liabilities assumed were initially recognized provisionally in the accompanying consolidated balance sheets at their estimated
fair values as of the acquisition date. The fair values as of the acquisition date are based on information that existed as of the acquisition
date. The Company completed its accounting for this acquisition during the period ended June 30, 2024. As a result of the completion of
the Company&#x2019;s analysis, the amount of provisional in-process research and development was determined to have a value of nil. Accordingly,
the amount of goodwill recognized was increased to include the previously recognized provisional amount of in-process research and development.
There was no impact to the Company&#x2019;s consolidated statement of operations as a result of this change to the provisional allocation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The acquisition-date
fair value of the consideration transferred totaled approximately $&lt;span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferredOther1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_pn5n6" title="Fair value of consideration transferred amount"&gt;156.6&lt;/span&gt; million, which consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_zcWWcXX4LyLf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zuXCouvoePbh" style="display: none"&gt;Schedule of acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--BusinessCombinationContingentConsiderationCommonStock_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_pp0p0" style="width: 18%; text-align: right" title="Common stock"&gt;136,001,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--BusinessCombinationContingentConsiderationAsset_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration"&gt;20,557,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;156,559,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zSazFVVEEJqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
fair value of the Company&#x2019;s common shares issued as consideration was based on the closing price of the Company&#x2019;s common stock
as of the Acquisition Date. The fair value of the contingent consideration was based on the Sellers&#x2019; right to receive additional
shares of common, pro rata, upon the exercise or conversion of warrants, options and convertible notes payables outstanding as of the
Closing Date. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;The
following table details the provisional fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zTMLAtYSEMng" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zDv9jLSHgYQ" style="display: none"&gt;Schedule of fair value of assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20240213_us-gaap--BusinessAcquisitionAxis_custom--GEDiCubeMember" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;65,851&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating lease ROU&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;624,366&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Assets Acquired:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;858,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;583,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;722,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;624,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,832,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Liabilities Assumed&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,762,913&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Assets Acquired&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,904,909&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Goodwill_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;159,464,040&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;156,559,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zIqslQ0D0hg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of Gedi Cube. None of the goodwill is expected
to be deductible for income tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The amounts
of revenue and loss of Renovaro Cube, included in the Company&#x2019;s condensed consolidated statements of operations from the three months
ended September 30, 2024 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_z7M74Jv2bGJ8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zTkORqMmuyAf" style="display: none"&gt;Schedule of consolidated statements of operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20240701__20240930__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zBUKp80SXmMe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--BusinessAcquisitionsRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessAcquisitionsNetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;(48,406,163&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zxM8GUXlTLY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Consolidated
unaudited pro forma information: &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the three-month
period ended September 30, 2023. These amounts have been estimated after applying the Company&#x2019;s accounting policies:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zx0AnPw0nq3c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zLsoTx81k016" style="display: none"&gt;Schedule of consolidated proforma information&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230701__20230930__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zVXn0a0PPmR9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--BusinessAcquisitionsProFormaRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;(13,146,452&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_ztDq6T5ZHSUb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0; background-color: white"&gt;The
unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results
of operations would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future
results of operations.&lt;/p&gt;

</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="From2024-02-122024-02-13_custom_GEDiCubeMember"
      decimals="-5"
      id="Fact000901"
      unitRef="USD">156600000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000903">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_zcWWcXX4LyLf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zuXCouvoePbh" style="display: none"&gt;Schedule of acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--BusinessCombinationContingentConsiderationCommonStock_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_pp0p0" style="width: 18%; text-align: right" title="Common stock"&gt;136,001,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--BusinessCombinationContingentConsiderationAsset_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration"&gt;20,557,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;156,559,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock>
    <RENB:BusinessCombinationContingentConsiderationCommonStock
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">136001631</RENB:BusinessCombinationContingentConsiderationCommonStock>
    <us-gaap:BusinessCombinationContingentConsiderationAsset
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">20557500</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2024-02-122024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000909"
      unitRef="USD">156559131</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000913">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zTMLAtYSEMng" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zDv9jLSHgYQ" style="display: none"&gt;Schedule of fair value of assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20240213_us-gaap--BusinessAcquisitionAxis_custom--GEDiCubeMember" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;65,851&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating lease ROU&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;624,366&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Assets Acquired:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;858,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;583,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;722,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;624,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,832,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Liabilities Assumed&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,762,913&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Assets Acquired&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,904,909&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Goodwill_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;159,464,040&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;156,559,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000915"
      unitRef="USD">65851</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000917"
      unitRef="USD">151544</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000919"
      unitRef="USD">16243</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000921"
      unitRef="USD">624366</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000923"
      unitRef="USD">858004</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000925"
      unitRef="USD">583577</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000927"
      unitRef="USD">722509</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000929"
      unitRef="USD">624367</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000931"
      unitRef="USD">1832460</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">3762913</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000935"
      unitRef="USD">-2904909</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">159464040</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">156559131</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <RENB:ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000941">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_z7M74Jv2bGJ8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zTkORqMmuyAf" style="display: none"&gt;Schedule of consolidated statements of operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20240701__20240930__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zBUKp80SXmMe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--BusinessAcquisitionsRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessAcquisitionsNetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;(48,406,163&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</RENB:ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock>
    <RENB:BusinessAcquisitionsNetIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">-48406163</RENB:BusinessAcquisitionsNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000947">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zx0AnPw0nq3c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zLsoTx81k016" style="display: none"&gt;Schedule of consolidated proforma information&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230701__20230930__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zVXn0a0PPmR9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--BusinessAcquisitionsProFormaRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;(13,146,452&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="From2023-07-012023-09-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000951"
      unitRef="USD">-13146452</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-07-01to2024-09-30" id="Fact000953">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zgEkA8yPRya" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 12 &#x2014; &lt;span id="xdx_82A_zj80IHd0CFql"&gt;SUBSEQUENT EVENTS&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;From October 21, 2024, to November
6, 2024, the Company issued Promissory Notes in the aggregate principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20241106_pp0p0" title="Principal amount"&gt;900,000&lt;/span&gt;. The Notes bear an interest rate ranging from
&lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20241021__20241106__srt--RangeAxis__srt--MinimumMember_zqzPZX4jr8if" title="Interest rate"&gt;10%&lt;/span&gt; to &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20241021__20241106__srt--RangeAxis__srt--MaximumMember_zJvMxE6ns7D6" title="Interest rate"&gt;12%&lt;/span&gt; per annum and mature from &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20241021__20241106__srt--RangeAxis__srt--MinimumMember_zkXriJD5qNo2" title="Maturity date"&gt;December 31, 2024&lt;/span&gt;, to &lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20241021__20241106__srt--RangeAxis__srt--MaximumMember_zg5Nf6c8Jhz7" title="Maturity date"&gt;January 31, 2025&lt;/span&gt; (the &#x201c;Maturity Date&#x201d;). The Company is required
to pay principal and interest on the Maturity Date.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On October 17, 2024, the Company
entered into an investor relations consulting agreement with MZHCI, LLC. Pursuant to the agreement, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241001__20241017__srt--CounterpartyNameAxis__custom--MZHCILLCMember_pdd" title="Stock issued during period"&gt;160,000&lt;/span&gt; shares
of Common Stock to MZHCI, LLC valued at $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241001__20241017__srt--CounterpartyNameAxis__custom--MZHCILLCMember_pp0p0" title="Stock issued during period, value"&gt;118,400&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;On October 14, 2024, the
Company issued&#160;&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241001__20241014__srt--CounterpartyNameAxis__custom--DavidWeinsteinMember_pdd" title="Stock issued during period"&gt;250,000&lt;/span&gt;&#160;shares of Common Stock as part of a sign on bonus valued at $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241001__20241014__srt--CounterpartyNameAxis__custom--DavidWeinsteinMember_pp0p0" title="Stock issued during period, value"&gt;137,500&lt;/span&gt; to the Chief Executive Officer effective
October 14, 2024, David Weinstein.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;On October 14, 2024, the
Company issued&#160;&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241001__20241014__srt--ProductOrServiceAxis__custom--ConsultingServicesMember_pdd" title="Stock issued for services"&gt;500,000&lt;/span&gt;&#160;shares of Common Stock for consulting services valued at $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241001__20241014__srt--ProductOrServiceAxis__custom--ConsultingServicesMember_pp0p0" title="Stock issued for services, value"&gt;275,000&lt;/span&gt;.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Related to the June 2024 Private
Placement, ranging from October 2, 2024, to October 10, 2024, the Company sold&#160;190,140 Units at a price per Unit equal to $1.4726&#160;to
a certain investor who paid in cash an aggregate amount of $280,000&#160;in consideration of the Units.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-11-06"
      decimals="0"
      id="Fact000955"
      unitRef="USD">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-10-212024-11-06_srt_MinimumMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-10-212024-11-06_srt_MaximumMember"
      decimals="INF"
      id="Fact000959"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-10-212024-11-06_srt_MinimumMember"
      id="Fact000961">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-10-212024-11-06_srt_MaximumMember"
      id="Fact000963">2025-01-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-012024-10-17_custom_MZHCILLCMember"
      decimals="INF"
      id="Fact000965"
      unitRef="Shares">160000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-012024-10-17_custom_MZHCILLCMember"
      decimals="0"
      id="Fact000967"
      unitRef="USD">118400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-012024-10-14_custom_DavidWeinsteinMember"
      decimals="INF"
      id="Fact000969"
      unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-012024-10-14_custom_DavidWeinsteinMember"
      decimals="0"
      id="Fact000971"
      unitRef="USD">137500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-012024-10-14_custom_ConsultingServicesMember"
      decimals="INF"
      id="Fact000973"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-012024-10-14_custom_ConsultingServicesMember"
      decimals="0"
      id="Fact000975"
      unitRef="USD">275000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-07-01to2024-09-30" id="Fact000976">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-07-01to2024-09-30" id="Fact000977">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-07-01to2024-09-30" id="Fact000978">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-07-01to2024-09-30" id="Fact000979">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
